- Home
- TNXP vs ALEC Comparison
TNXP vs ALEC Comparison
Compare TNXP & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- ALEC
- Stock Information
- Founded
- TNXP 2007
- ALEC 2013
- Country
- TNXP United States
- ALEC United States
- Employees
- TNXP N/A
- ALEC N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TNXP Health Care
- ALEC Health Care
- Exchange
- TNXP Nasdaq
- ALEC Nasdaq
- Market Cap
- TNXP 118.2M
- ALEC 101.1M
- IPO Year
- TNXP N/A
- ALEC 2019
- Fundamental
- Price
- TNXP $18.83
- ALEC $1.17
- Analyst Decision
- TNXP Strong Buy
- ALEC Buy
- Analyst Count
- TNXP 2
- ALEC 7
- Target Price
- TNXP $585.00
- ALEC $4.70
- AVG Volume (30 Days)
- TNXP 573.9K
- ALEC 928.9K
- Earning Date
- TNXP 05-20-2025
- ALEC 05-08-2025
- Dividend Yield
- TNXP N/A
- ALEC N/A
- EPS Growth
- TNXP N/A
- ALEC N/A
- EPS
- TNXP N/A
- ALEC N/A
- Revenue
- TNXP $10,094,000.00
- ALEC $88,339,000.00
- Revenue This Year
- TNXP $12.17
- ALEC N/A
- Revenue Next Year
- TNXP $789.15
- ALEC $376.51
- P/E Ratio
- TNXP N/A
- ALEC N/A
- Revenue Growth
- TNXP 29.94
- ALEC N/A
- 52 Week Low
- TNXP $6.76
- ALEC $0.87
- 52 Week High
- TNXP $672.00
- ALEC $6.78
- Technical
- Relative Strength Index (RSI)
- TNXP 53.35
- ALEC 51.49
- Support Level
- TNXP $18.55
- ALEC $0.97
- Resistance Level
- TNXP $21.99
- ALEC $1.34
- Average True Range (ATR)
- TNXP 1.53
- ALEC 0.11
- MACD
- TNXP 0.22
- ALEC 0.01
- Stochastic Oscillator
- TNXP 58.64
- ALEC 53.68
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.